Professor David Harris

Renal Failure Research Group

• Research Interests
• Publications
• Contact Details

David Harris is Professor of Medicine and Associate Dean and Head of Western Clinical School. He is Director of the Renal Failure Laboratory in the Centre for Transplantation and Renal Research, Westmead Millennium Institute, and a nephrologist at Westmead and Blacktown Hospitals.

He is immediate Past-President of the Australian and New Zealand Society of Nephrology, Chairman of the Medical and Scientific Advisory Committee of Kidney Health Australia (KHA) and Director of KHA. He is Editor-in-Chief of the journal Nephrology, the official journal of the Asian/Pacific Society of Nephrology. He is on the Executive of the Asian Pacific and International Societies of Nephrology. He is one of the chief investigators of the Centre for Clinical Research Excellence (CCRE) in Renal Medicine, which includes clinician scientists in the Departments of Nephrology at Westmead, Westmead Children's and Royal Prince Alfred Hospitals in Sydney and Monash Medical Centre in Melbourne.

His major clinical interests are the prevention and management of chronic renal disease, as well as the management of patients with endstage renal failure by peritoneal and haemodialysis.

Research Interests

David is Chief Investigator of the IDEAL Trial, a multi-national NHMRC- and AHMAC-funded trial examining the correct time to initiate dialysis for endstage renal failure.

As Chief Investigator in the CCRE he will help co-ordinate a project examining urinary protein and albumin excretion as a screening tool for chronic kidney disease.

His laboratory interests are focused on the progression of chronic renal disease, and his group has played a major role in demonstrating the importance of renal cell metabolism, proteinuria, renal cell pro-inflammatory change, oxidant injury, NFkB and interstitial inflammation to disease progression.

His group is investigating novel therapies, including DNA vaccination and regulatory lymphocyte and macrophage, to slow progressive disease.

Publications

• Articles from Peer Reviewed Journals
• Invited Editorials, Articles and Reviews

Articles from Peer Reviewed Journals

- 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 -

2006

• Zheng, G, Wang, Y, Xiang, S, Tay, Y, Wu, H, Watson, D, Coombes, J, Rangan, G, Alexander, S, Harris, D. DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury. Journal of the American Society of Nephrology : JASN. 2006; 17:465-74 [Abstract]
• Wang, Y, Zhang, G, Wang, Y, Hu, M, Wu, H, Watson, D, Hori, S, Alexander, I, Harris, D, Alexander, S. Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin. Journal of the American Society of Nephrology : JASN. 2006; 17:697-706 [Abstract]
• Zhu, G, Wang, Y, Wang, J, Tay, Y, Yung, T, Rangan, G, Harris, D. Significance of CD25 positive cells and macrophages in noncrescentic IgA nephropathy. Renal failure. 2006; 28:229-35 [Abstract]
• Zheng, G, Zheng, L, Wang, Y, Wu, H, Kairaitis, L, Zhang, C, Tay, Y, Wang, Y, Alexander, S, Harris, D. NK cells do not mediate renal injury in murine adriamycin nephropathy. Kidney international. 2006; 69:1159-65 [Abstract]
• Lee, V, Wang, Y, Qin, X, Wang, Y, Zheng, G, Mahajan, D, Coombes, J, Rangan, G, Alexander, S, Harris, D. Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2006; 21:3293-8 [Abstract]
• Mahajan, D, Wang, Y, Qin, X, Wang, Y, Zheng, G, Wang, Y, Alexander, S, Harris, D. CD4+CD25+ Regulatory T Cells Protect against Injury in an Innate Murine Model of Chronic Kidney Disease. Journal of the American Society of Nephrology : JASN. 2006; 17:2731-41 [Abstract]
• Qin, X, Lee, V, Wang, Y, Zheng, G, Wang, Y, Alexander, S, Harris, D. A protective role for programmed death 1 in progression of murine adriamycin nephropathy. Kidney international. 2006; 70:1244-50 [Abstract]

2005

• Disney, A, de Jersey, P, Kirkland, G, Mantha, M, Charlesworth, J, Gallagher, M, Harris, D, Gock, H, Mangos, G, MacMillan, J, Viswalingam, A. Aranesp (R) (darbepoetin alfa) administered once monthly (QM) maintains hemoglobin (Hb) levels in chronic kidney disease (CKD) patients. Nephrology Dialysis Transplantation. 2005; 20:V254-V255 [Abstract]
• Wavamunno, M, Harris, D. The need for early nephrology referral. Kidney international. Supplement. 2005; 67:S128-32 [Abstract]
• Zheng, G, Wang, Y, Mahajan, D, Qin, X, Wang, Y, Wang, Y, Alexander, S, Harris, D. The role of tubulointerstitial inflammation. Kidney international. Supplement. 2005; 67:S96-100 [Abstract]
• Rangan, G, Wang, Y, Tay , Y, Coombes, J, Harris, D. Effect of nephrotoxins on tubulointerstitial injury and NF-kappaB activation in Adriamycin nephropathy. Renal failure. 2005; 27:609-14 [Abstract]
• Zhu, G, Li, R, Harris, D. The role of tubulointerstitial inflammation cells in human IgA nephropathy. Chinese Journal of Nephrology. 2005; 21:256-259
• Tay , Y, Wang, Y, Kairaitis, L, Rangan, G, Zhang, C, Harris, D. Can murine diabetic nephropathy be separated from superimposed acute renal failure?. Kidney international. 2005; 68:391-8 [Abstract]
• Lee, J, Simmons, A, Odell, R, Botto, S, Faramus, E, Schindhelm, K, Roeth, P, Nair, H, Harris, D. Hematologic and biochemical effects of the Gradiflow in an ex vivo ovine model. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2005; 51:366-71 [Abstract]
• Rangan, G, Wang, Y, Tay , Y, Harris, D. Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2005. p. 1013-4. [Abstract]
• Wang, Y, Mahajan, D, Tay, Y, Bao, S, Spicer, T, Kairaitis, L, Rangan, G, Harris, D. Partial depletion of macrophages by ED7 reduces renal injury in Adriamycin nephropathy. Nephrology ( Carlton , Vic.). 2005; 10:470-7 [Abstract]
• Kairaitis, L, Wang, Y, Gassmann, M, Tay , Y, Harris, D. HIF-1 alpha expression follows microvascular loss in advanced murine adriamycin nephrosis. American Journal of Physiology-Renal Physiology. 2005; 288:F198-F206 [Abstract]
• Alfred, S, Coleman, P, Harris, D, Wigmore, T, Stachowski, E, Graudins, A. Delayed neurologic sequelae resulting from epidemic diethylene glycol poisoning. Clinical Toxicology. 2005; 43:155-9 [Abstract]
• Wu, H, Wang, Y, Tay, Y, Zheng, G, Zhang, C, Alexander, S, Harris, D. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney international. 2005; 67:2178-86 [Abstract]

2004

• Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn, K, Parnham A, Pascoe R, Voss D, Walker R, Levin A. The effect of Early and Late Intervention with epoetin alfa on left ventricular mass in patients with chronic kidney disease (stages 3 and 4); results of a randomised clinical trial. J Am Soc Nephrol 2004; 15: 148-156.
• Cooper B, Harris DCH, Pollock CA. The Initiating Dialysis Early and Late (IDEAL) study: study rationale and design. Periton Dial Int 2004; 24: 176-81.

• McMahon LP, Roger SD, Levin A and the SLIMHEART Investigators Group. The development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647.

• Wang Y, Tay YC, Harris DCH. Proximal tubule cells stimulated by lipopolysaccharide inhibit macrophage activation. Kidney Int 2004; 66: 655-662.

• Sadlier DM, Connolly SB, Kieran NE, Roxburgh S, Brazil D, Kairaitis L, Wang Y, Harris DCH, Doran P, Brady HR. Sequential extracellular matrix-focused and baited-global cluster analysis of serial transcriptomic profiles identifies candidate modulators of renal tubulointerstitial fibrous in a murine adriamycin induced nephropathy. J Biol Chem 2004; 279: 29670-29680.

2003

• Kairaitis L, Wang Y-P, Tay Y-C, Wang Y, Harris DCH. Blockade of CD40-CD40 ligand protects renal injury in chronic proteinuric renal disease. Kidney Int 2003; 64: 1265-1272.

2002

• Rangan GK, Wang Y-P, Harris DCH. Dietary quercetin augments activator protein-1 and does not reduce nuclear factor 6B in the renal cortex of rats with established chronic glomerular disease. Nephron 2002; 3: 313-319.
• Wang Y-P, Tay Y-C, Rangan GK, Wang Y, Harris DCH. Transfection of tubular cells with Fas Ligand causes leukocyte apoptosis. Kid Int 2002;61:1303-1311.
• Vanrenterghem Y, Barany P, Mann J, Kerr P, Wilson J, Baker N and Gray SJ. Randomised Trial of ARANESP™ for maintaining haemoglobin at a reduced dose frequency compared with epoetin in dialysis patients. Kid Int 2002; 62: 2167-2175.

2001

• Wang Y-P, Wang Y, Feng X, Rangan GK, Harris DCH. Depletion of CD4+ T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kid Int 2001; 59: 975-984.

• Wang Y, Wang Y-P, Tay Y-C, Harris DCH. Role of CD8+ cells in the progression of murine adriamycin nephropathy. Kid Int 2001; 59: 941-949.

• Harris DCH, Wang Y, Campbell D. Regulation of tubular cell MCP-1 production by intracellular ions; a role for sodium and calcium. Exp Nephrol. 2001; 9: 205-213.

• Rangan GK, Wang Y-P, Harris DCH. Pharmacological modulators of nitric oxide exacerbate tubulointerstitial injury in proteinuric rats. J Am Soc Nephrol 2001; 12: 1696-1705.

• Chen L, Wang Y, Kairaitis LK, Wang Y, Zhang B-H, Harris DCH. Molecular mechanisms by which iron induces nitric oxide synthesis in cultured proximal tubule cells. Exp Nephrol 2001; 9: 198-204.

• Rangan GK, Wang Y-P, Tay Y-C, Harris DCH. Induction of proteinuric chronic glomerular disease in the rat by an intracardiac injection of doxorubicin hydrochloride. Contemp Topics Lab Animal Science 2001; 40: 44-49.

• Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ on behalf of the European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747.

• Rangan GK, Wang Y-P, Tay Y-C, Harris DCH. Early administration of PDTC in Adriamycin nephropathy; effect on proteinuria, cortical tubulointerstitial injury and NF-kB activation. Renal Failure 2001; 23: 773-780.

• Chao A, Daley T, Gruenewald S, Larcos G, Harris DCH, Yuill E, Allen R.Duplex ultrasound criteria for assessment of stenoses of radiocephalic haemodialysisfistulae. J Vascular Technology 2002; 23: 773-780.

2000

• Rangan GK, Wang Y-P, Tay Y-C, Harris DCH. Cytokine gene expression in Adriamycin nephropathy; effects of antioxidant nuclear factor - kB inhibitors in established disease. Nephron 2000; 86: 4: 482-490.

• Kairaitis L, Yuill E, Harris DCH. Determinants of haemoglobin carbamylation in haemodialysis and peritoneal dialysis patients. Nephrol Dial Transpl 2000; 15:431-7.

• Wang Y-P, Rangan GK, Goodwin B, Tay Y-C, Wang Y, Harris DCH. Lipopolysaccharide-induced MCP-1 gene expression in rat tubular epithelial cells is NFkB dependent. Kid Int 2000; 57: 2011-2022.

• Wang Y, Wang Y-P, Tay Y-C, Harris DCH. Progressive adriamycin nephropathy in mice: Sequence of histological and immunohistochemical events. Kid Int 2000; 58: 1797-1804.
  Full characterisation of a useful and relevant new murine model of progressive chronic renal disease.

Invited Editorials, Articles and Reviews

- 2005 - 2004 - 2003 - 2002 - 2001 -

2005

• Rangan G, Harris DCH. Retardation of renal failure – applying principles to practice. Annals, Academy of Medicine, Singapore 2005; 34: 1: 16-24.

2004

• Harris DCH. Editorial. Nephrology 2004: 9; 1.
• Zheng, G, Harris, D. Plasmin in renal interstitial fibrosis: innocent or guilty?. Kidney international. 2004; 66:455-6 [Abstract]

2003

• Johnson, D, Agar, J, Collins, J, Disney, A, Harris, D, Ibels, L, Irish, A, Saltissi, D, Surnayi, M. Recommendations for the use of icodextrin in peritoneal dialysis patients. Nephrology. 2003; 8:1-7
• Rangan G, Harris DCH. A blast from the mast. Kid Int 2003; 64: 1134-5.

2002

• Thomas M, Harris DCH. Management of bacterial peritonitis and exit site infections in continuous ambulatory peritoneal dialysis . Nephrology, 2002; 7: 267-271.

• Thomas M, Harris DCH. Problems in continuous renal replacement therapy. Nephrology 2002; 7: 110-114.

• Amgen Anaemia Advisory Group. Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia. Nephrology 2002; 7: S173 – S180.

• Barraclough DR, Harris DCH & Australian COX-2 - Specific Inhibitor Prescribing Group. Considerations for safe prescribing and use of COX-2 specific inhibitor. MJA: 2002 176: 328-331.

• Harris DCH. Renal and BP effect of NSAIDs and coxibs in elderly. Commentary for Medical Observer/Australian Doctor 2002.

• Thomas M, Harris DCH. Renal effects of cyclo-oxygenase-2 inhibition. Nephrology 2002; 7 281-286.

• Harris D, Collins J, Disney A, Hawley C, Irish A, Kerr P, Makris A, Lynn K, Pollock C, Roger S, Walker R, Walker R. Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia. Nephrology 2002: 7: 315-323.

2001

• Harris DCH. Tubulointerstitial disease. Current Opinion in Nephrology and Hypertension 2001; 10: 303-313.
• Harris DCH. Fat kidneyed. Kid Int 2001; 59: 2368-2369.
• Kairaitis L, Harris DCH. Tubular interstitial interactions in proteinuria. Nephrology, 2001; 6: 198-207.

Contact Details

T +61 2 9845 8938

F +61 2 9891 3749

E dch@med.usyd.edu.au